Carryl M

Indicated as an adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes who are already treated with a combination of Gliclazide (Carryl M) and Metformin (Carryl M) or whose diabetes is not adequately controlled with Metformin (Carryl M) alone, or for those patients who have initially responded to Gliclazide (Carryl M) alone and require additional glycaemic control.

1-2 tab once or bid. Max: 4 tab/day.

1. Known hypersensitivity to Gliclazide (Carryl M) or Metformin (Carryl M) or any components of Carryl M

2. Renal disease or renal dysfunction (e.g., as suggested by serum creatinine levels ³ 1.5 mg/dL [males], ³ 1.4 mg/dL [females] or abnormal creatinine clearance), which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia

3. Congestive heart failure requiring pharmacologic treatment

4. Known hypersensitivity to this product or any of its components.

5. Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. Diabetic ketoacidosis should be treated with insulin

6.

Patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials, because use of such products may result in acute alteration of renal function.

May decrease Metformin (Carryl M) elimination w/ cationic drugs eg amiloride, cimetidine, digoxin, morphine, procainamide, quinidine, ranitidine, vancomycin. Increased hypoglycemic effect of Gliclazide (Carryl M) w/ miconazole & phenylbutazone. Increased Metformin (Carryl M) plasma C_max & AUC w/ furosemide. Block absorption of vit B₁₂. Enhance Metformin (Carryl M) absorption w/ nifedipine. Salicylates & thiazide diuretics.

GI disturbances, skin reaction, leucopenia, thrombocytopenia, agranulocytosis, haemolytic anaemia, cholestatic jaundice, vomiting, diarrhoea, gastritis, increased transaminases.